Metformin's case as an anti-ageing drug now rests on three null results
Twenty-one years of cancer follow-up, multimorbidity data to 2021, and a randomised trial in frail older adults. In each, metformin did not beat placebo. Lifestyle change did.
An A1c estimates average glucose. For some people the estimate is systematically off.
The equation converting A1c to average glucose was built from 507 people. In carriers of sickle cell trait the reading runs about 0.3 percentage points low for the same measured glucose.
Glucose monitors are the new wellness accessory. 23 studies ask who actually benefits.
A meta-analysis of continuous glucose monitors in people without diabetes found a real effect on blood sugar — but only in those with prediabetes. In healthy users, the evidence for a metabolic benefit was not there.
An app matched human coaches in a diabetes trial. Both worked about a third of the time.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
Two November studies try to define a normal glucose curve in healthy people
One proposes a rate-of-change benchmark from 153 non-diabetic wearers. The other put ten young adults through food, exercise and a laboratory stress test to see what actually moves the line.
Digital therapy for panic disorder worked far better with a clinician attached
Across 40 trials, self-guided apps moved panic severity modestly and barely touched fear-related cognitions. Clinician-guided versions moved both — which complicates the scalability pitch.